Description
PrymaLab · Research Use Only
Survodutide 10mg
Still in development · which means the record has not settled
Survodutide is in active clinical development, which is a state nothing else in this catalogue occupies. The others here are approved, abandoned, or were never filed at all. A live programme means the published record on this one is interim, and interim records change.
Specification Table
| Property | Value |
|---|---|
| Compound | Survodutide |
| Development code | BI 456906 |
| Class | Acylated peptide agonist at two receptors |
| Residue count | 29 |
| Sequence basis | Built on the glucagon sequence with several positions substituted |
| Positions substituted toward GLP-1 | Reported at positions 18, 20 and 23 |
| Further substitution | Position 16, reported as an exendin-4 residue |
| Acylation | A fatty diacid attached to a lysine side chain at position 24 |
| Purpose of the acylation | Extension of circulating half-life through albumin binding |
| Receptors engaged | The glucagon receptor and the GLP-1 receptor |
| Development status | Active clinical programme. Not approved in any jurisdiction |
| What that implies | The published record is interim and will be added to |
| Appearance | White lyophilized powder |
| Purity | Per lot-specific certificate of analysis |
| Storage, lyophilized | 2-8°C short term, -20°C for extended storage, protected from light and moisture |
What Does an Unfinished Survodutide Programme Mean?
Most compounds in this catalogue sit in one of three settled states, and survodutide does not.
Some hold an approval. A regulator examined a complete dossier and reached a conclusion that can be read.
Some were abandoned, which means the record stops at whatever phase the sponsor reached and no more is coming.
Most were never filed at all, so the record is animal work and whatever independent groups chose to publish.
Survodutide is in none of those states. Its programme is running, which has three consequences a researcher should account for.
The first is that the published record is partial by construction. Results appear as trials complete, and the trials still running will add to what is known.
The second is that early-phase findings can be revised. A signal reported in a smaller study may or may not survive a larger one, and the larger one may not have reported yet.
The third is that the record is unusually good for its stage. A live commercial programme generates controlled trials to regulatory standard, which is better evidence than almost anything else in this catalogue rests on.
So the position is genuinely mixed. Better data than most compounds here, and less settled than any of them.
The practical instruction is to check publication dates and to check whether a more recent result exists, which is not necessary for a compound whose programme ended a decade ago.
What Does Engaging Two Receptors Change?
Survodutide was designed to activate two different receptors rather than one, and that is a deliberate choice with a specific rationale.
The two receptors sit at opposite ends of a related family and their natural ligands do different things.
One is engaged by a hormone that reduces intake and slows gastric emptying. The other by a hormone associated with raising energy expenditure and mobilising stored substrate.
Historically those two were treated as opposing, which made combining them counterintuitive.
The design argument is that they act on different arms of energy balance, so engaging both addresses intake and expenditure simultaneously rather than cancelling out.
Whether that argument holds is precisely what the clinical programme is testing, and it is not a settled question.
For an experiment the important consequence is that a dual agonist cannot be treated as a single-target tool.
Any observed effect has two candidate routes, and separating them requires either a receptor-null system or a selective antagonist at one of the two.
That is the same methodological point the hexarelin page makes about CD36, arrived at from a completely different direction, and it applies with more force here because both targets are intended rather than incidental.
The ratio of activity at the two receptors is also a design parameter rather than a fixed property, so comparing across dual agonists means comparing ratios rather than potencies.
What Does the Acylation Do?
A fatty diacid chain is attached to a lysine side chain of survodutide, and its function is entirely about how long the molecule persists.
A 29-residue peptide with no modification is cleared quickly, by renal filtration and by proteolysis, on a timescale that makes sustained exposure impractical.
The fatty chain binds serum albumin reversibly, which creates a circulating reservoir. Bound molecules are protected and released gradually as free molecules are cleared.
That is a well-established half-life extension strategy and it is the same approach used across this class of compound.
It has consequences for laboratory work that the pharmacology papers do not emphasise.
An albumin-binding molecule behaves differently in a system containing serum than in one that does not. Free concentration in a serum-containing medium is lower than the nominal concentration added.
That means the same nominal concentration produces different exposure in serum-free and serum-containing conditions, which is a real confound when comparing across assay formats.
The lipid chain also raises surface activity. The molecule accumulates at air-liquid interfaces and adsorbs more readily than an unmodified peptide would.
Gentle reconstitution and low-binding consumables are therefore not optional here, and the caution matters more at low working concentration.
Recording whether a medium contained serum, and at what percentage, belongs alongside the concentration for any acylated compound.
What Should the Certificate Show?
A survodutide certificate carries seven fields, and two exist because of the acylation.
The sequence written out, since a 29-residue peptide with several substitutions is not identifiable from a name or a development code.
Observed mass against calculated mass, with the calculated figure stated and the instrument resolution given.
Confirmation that the acylation is present, since an unacylated preparation has the same sequence, a substantially lower mass, and entirely different behaviour.
The attachment site of the acyl group, because acylation chemistry can target more than one lysine and a chain on the wrong one gives the correct mass and the wrong molecule.
Purity by reverse-phase HPLC with the chromatogram supplied, since deletion sequences on a 29-mer resolve by retention more reliably than by mass.
Counterion identity and net peptide content, plus lot number and synthesis date.
A certificate that confirms both the presence and the position of the acyl group has answered the questions that distinguish this compound from a peptide sharing its sequence, and most stop at the mass.
What Should a Study Design Account For?
Survodutide has a live programme and two targets, which carries a specific set of design obligations worth listing together.
The first is dating. Any figure taken from the literature should carry the year it was published, because a more recent trial may have revised it.
That is a habit rather than a burden and it costs one field in a reference list.
The second is the two-receptor problem. An effect observed with this compound has two candidate routes and attributing it to either requires a control that isolates one.
A receptor-null system does that cleanly, a selective antagonist does it adequately, and running the compound alone does not do it at all.
The third is the albumin question. In any medium containing serum, free concentration is lower than nominal concentration, and the gap depends on the serum percentage.
Comparing a serum-free result against a serum-containing one without accounting for that compares two different exposures rather than two different conditions.
The fourth is the comparison set. Several compounds engage this pair of receptors and they differ in the ratio of activity between the two.
Comparing across them means comparing ratios rather than potencies, and a paper reporting only one number for a dual agonist has reported half of what the comparison needs.
None of that is unusual practice. It is unusual in this market, which is where the gap sits and why it is worth writing down on a product page.
How Should the Vial Be Handled?
Handling survodutide follows from the acylation more than from the sequence.
Sealed dry material holds at 2 to 8 degrees Celsius for short periods and at minus 20 for longer, kept dark and dry throughout.
Bring the vial to ambient temperature before opening, since the powder is hygroscopic and cold glass condenses water onto the cake.
Reconstitute slowly down the wall and swirl gently rather than shaking. The lipid chain makes this molecule markedly more surface-active than an unmodified peptide of the same length.
Acylated peptides can also be slow to dissolve fully, and the correct response is standing time rather than agitation.
Aliquot on first reconstitution. Freeze-thaw damage on a 29-residue chain appears as aggregation rather than as a mass change, which makes it invisible without a specific check.
Use low-binding consumables throughout, since surface activity and adsorption both scale with the lipid modification.
Record lot, net peptide content, diluent, and whether any medium the compound will meet contains serum and at what percentage.
That last field has no equivalent for an unmodified peptide and it is what makes an experiment with an albumin-binding compound reproducible.
One closing note that follows from the development status rather than from the chemistry.
A compound in an active programme attracts attention, and attention attracts material of uncertain provenance into the market around it.
The verification questions on this page matter more here than they would for a compound nobody is writing about.
One final point about working with a compound whose literature is still being written.
The papers available today describe a programme in motion, which means a figure quoted in a 2022 report may have been revised by a later one.
Anyone citing this material should check the publication date of every source before relying on a number from it.
That is ordinary practice in any fast-moving area.
It matters more here because survodutide has accumulated most of its record inside a span of about four years.
Published Literature
Selected references on the discovery of this compound and on its clinical evaluation to date.
- Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, et al. Molecular Metabolism. 2022;66:101633. DOI: 10.1016/j.molmet.2022.101633
- Le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Lancet Diabetes and Endocrinology. 2024;12(3):162-173. DOI: 10.1016/S2213-8587(23)00356-X
- Bluher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Diabetologia. 2024;67(3):470-482. DOI: 10.1007/s00125-023-06053-9
- Thomas L, Baader-Pagler T, Gruner S, Zimmermann T, Hennige AM, Wagner M, et al. Diabetes, Obesity and Metabolism. 2024;26(8):3372-3385. DOI: 10.1111/dom.15551
Frequently Asked Questions
What is survodutide?
A 29-residue acylated peptide, development code BI 456906, built on the glucagon sequence with several positions substituted and a fatty diacid attached to a lysine side chain.
Why is its development status worth stating?
Because the programme is still running, which nothing else in this catalogue is. Everything else here is approved, abandoned, or was never filed at all.
What follows from that?
The published record is partial by construction, early-phase findings can be revised by larger trials that have not reported, and the record is nonetheless better than most compounds here rest on.
What is the practical instruction?
Check publication dates and check whether a more recent result exists. That is unnecessary for a compound whose programme ended a decade ago and necessary here.
Which receptors does it engage?
The glucagon receptor and the GLP-1 receptor. The two sit at opposite ends of a related family and their natural ligands do different things.
Why combine them?
The design argument is that they act on different arms of energy balance, so engaging both addresses intake and expenditure simultaneously rather than cancelling out. That argument is what the programme is testing.
What does that mean experimentally?
A dual agonist cannot be treated as a single-target tool. Any observed effect has two candidate routes, and separating them needs a receptor-null system or a selective antagonist at one target.
What does the acylation do?
The fatty chain binds serum albumin reversibly, creating a circulating reservoir. Bound molecules are protected and released gradually as free molecules clear.
Does that affect laboratory work?
Substantially. Free concentration in a serum-containing medium is lower than the nominal concentration added, so the same figure produces different exposure in serum-free and serum-containing conditions.
What else does the lipid chain change?
It raises surface activity, so the molecule accumulates at air-liquid interfaces and adsorbs more readily than an unmodified peptide. Gentle handling and low-binding consumables are not optional.
What must the certificate confirm?
That the acylation is present and where it is attached. An unacylated preparation shares the sequence, has a substantially lower mass and behaves entirely differently.
What extra field belongs in the record?
Whether any medium the compound will meet contains serum and at what percentage. That has no equivalent for an unmodified peptide and it is what makes the work reproducible.
Compliance Statement
Survodutide is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, its clinical programme is ongoing so the published record is interim and results reported to date may be revised by trials that have not yet reported, it is not approved in any jurisdiction and material supplied here is not any investigational product supplied to a trial site, and no compound in this range is offered for any human or veterinary purpose. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
19 reviews for Survodutide 10mg